 CAMBRIDGE, England--BUSINESS WIRE--IONTAS Limited IONTAS, a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. NASDAQ: FSTX, has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137PD-L1 bispecific antibody. IONTAS applied its proprietary technology to generate a component utilized within FS222, which was subsequently licenced to F-star. The initiation of this trial adds to the growing portfolio of antib 